Obesity Update: Once-Monthly ASC30 Trial, Viking’s Phase III Launch, Generic Wegovy Win & More
In this week’s Obesity Updates, we spotlight the most pivotal developments reshaping obesity care—from next-gen GLP-1 trials and court victories to market-shifting access models and discontinued assets.
🔬 Key Highlights This Week:
💊 Ascletis initiates U.S. Phase IIa trial of ASC30, a once-monthly oral GLP-1R agonist
📈 Viking Therapeutics launches Phase III VANQUISH trial for VK2735 in obesity
⚖️ Viatris clears legal path for generic Wegovy with key patent court win
🔻 Roche shelves early-stage CT-173 following $2.7B Carmot acquisition
🌍 Global study finds universal GLP-1 access could cut obesity rates by 52% and save 37M lives in 5 years
Whether you’re a clinician, investor, or healthcare strategist, this episode delivers fast, expert-curated insights into the future of obesity innovation.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates
#ObesityResearch #GLP1 #VK2735 #ASC30 #Viatris #Wegovy #RochePharma #GlobalHealth #WeightLossDrugs #HealthcareInnovation #LucidQuest #PharmaNews #BiotechUpdates #ClinicalTrials